{"product_id":"arcoxia-etoricoxib-90mg-14tab","title":"ARCOXIA (ETORICOXIB) 90 MG 14 COMP","description":"\u003cp data-end=\"38\" data-start=\"0\"\u003e\u003cstrong data-end=\"38\" data-start=\"0\"\u003eARCOXIA (ETORICOXIB) 90 mg 14 COMP\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp data-end=\"217\" data-start=\"40\"\u003e\u003cstrong data-end=\"57\" data-start=\"40\"\u003eComparable a:\u003c\/strong\u003e Etoricoxib genérico\u003cbr data-end=\"80\" data-start=\"77\"\u003e\u003cstrong data-end=\"101\" data-start=\"80\"\u003eSustancia activa:\u003c\/strong\u003e Etoricoxib\u003cbr data-is-only-node=\"\" data-end=\"115\" data-start=\"112\"\u003e\u003cstrong data-end=\"133\" data-start=\"115\"\u003eConcentración:\u003c\/strong\u003e 90 mg\u003cbr data-end=\"142\" data-start=\"139\"\u003e\u003cstrong data-end=\"159\" data-start=\"142\"\u003ePresentación:\u003c\/strong\u003e Comprimidos\u003cbr data-end=\"174\" data-start=\"171\"\u003e\u003cstrong data-end=\"190\" data-start=\"174\"\u003eLaboratorio:\u003c\/strong\u003e MSD\u003cbr data-end=\"197\" data-start=\"194\"\u003e\u003cstrong data-end=\"208\" data-start=\"197\"\u003eOrigen:\u003c\/strong\u003e México\u003c\/p\u003e\n\u003cp data-end=\"567\" data-start=\"219\"\u003eEste medicamento se utiliza para el \u003cstrong data-end=\"297\" data-start=\"255\"\u003etratamiento del dolor y la inflamación\u003c\/strong\u003e en padecimientos como \u003cstrong data-end=\"337\" data-start=\"320\"\u003eosteoartritis\u003c\/strong\u003e, \u003cstrong data-end=\"362\" data-start=\"339\"\u003eartritis reumatoide\u003c\/strong\u003e, \u003cstrong data-end=\"393\" data-start=\"364\"\u003eespondilitis anquilosante\u003c\/strong\u003e, \u003cstrong data-end=\"421\" data-start=\"395\"\u003eataques agudos de gota\u003c\/strong\u003e y dolor agudo. El etoricoxib es un \u003cstrong data-end=\"498\" data-start=\"457\"\u003eantiinflamatorio no esteroideo (AINE)\u003c\/strong\u003e selectivo de la COX-2 que ayuda a reducir la inflamación y el dolor.\u003c\/p\u003e\n\u003cp data-is-only-node=\"\" data-is-last-node=\"\" data-end=\"719\" data-start=\"569\"\u003eEl consumo de este producto es responsabilidad de quien lo recomienda y de quien lo usa. Consulte a su médico antes de consumir cualquier medicamento.\u003c\/p\u003e\n\u003cdiv style=\"position: absolute; display: block; left: -1000px; top: 0px; width: 1px; height: 1px; overflow-x: hidden; overflow-y: hidden;\" id=\"__shopify_paste\"\u003e\n\u003cdiv style=\"font-family: arial; font-size: 12px; zoom: 1;\" dir=\"ltr\"\u003e\u003cspan id=\"result_box\" lang=\"en\"\u003e\u003cspan title=\"\"\u003eTHERAPEUTIC INDICATIONS:\u003cbr\u003e\u003cbr\u003e\u003c\/span\u003e\u003cspan title=\"\"\u003eARCOXIA ® is indicated for:\u003cbr\u003e\u003cbr\u003e\u003c\/span\u003e\u003cspan title=\"\"\u003e• Acute and chronic treatment of signs and symptoms of osteoarthritis and rheumatoid arthritis.\u003cbr\u003e\u003cbr\u003e\u003c\/span\u003e\u003cspan title=\"\"\u003e• Treatment of ankylosing spondylitis.\u003cbr\u003e\u003cbr\u003e\u003c\/span\u003e\u003cspan title=\"\"\u003e• Treatment of acute gouty arthritis.\u003cbr\u003e\u003cbr\u003e\u003c\/span\u003e\u003cspan title=\"\"\u003e• Relief of acute and chronic pain.\u003cbr\u003e\u003cbr\u003e\u003c\/span\u003e\u003cspan title=\"\"\u003e• Treatment of primary dysmenorrhea.\u003cbr\u003e\u003cbr\u003e\u003c\/span\u003e\u003cspan title=\"\"\u003eThe decision to prescribe a selective inhibitor of COX-2 should be based on individual assessment of every patient's risks (see WARNINGS).\u003cbr\u003e\u003cbr\u003e\u003c\/span\u003e\u003cspan title=\"\"\u003eCONTRAINDICATIONS: ARCOXIA ® is contraindicated in patients with hypersensitivity to any component of this product.\u003cbr\u003e\u003cbr\u003e\u003c\/span\u003e\u003cspan title=\"\"\u003eCongestive heart failure (class II-IV NYHA).\u003cbr\u003e\u003cbr\u003e\u003c\/span\u003e\u003cspan title=\"\"\u003eEstablished ischemic heart disease, peripheral arterial disease and \/ or cerebral vascular disease (including patients who have recently undergone coronary revascularization or angioplasty).\u003cbr\u003e\u003cbr\u003e\u003c\/span\u003e\u003cspan title=\"\"\u003eGENERAL PRECAUTIONS: Clinical studies suggest that the class of selective inhibitors of COX-2 may be associated, compared to placebo and some NSAIDs (naproxen), with increased risk of thrombotic events (specifically myocardial infarction and stroke) \u003c\/span\u003e\u003cspan title=\"\"\u003e. \u003c\/span\u003e\u003cspan title=\"\"\u003eAs the cardiovascular risks of selective inhibitors of COX-2 may increase with dose and duration of treatment, use the lowest effective daily dose for the shortest time possible. \u003c\/span\u003e\u003cspan title=\"\"\u003eShould periodically re-evaluate the symptoms and treatment response according to patient needs.\u003cbr\u003e\u003cbr\u003e\u003c\/span\u003e\u003cspan title=\"\"\u003ePatients with significant risk factors for cardiovascular events (eg hypertension, hyperlipidemia, diabetes mellitus, smoking) should only be treated with etoricoxib after careful consideration.\u003cbr\u003e\u003cbr\u003e\u003c\/span\u003e\u003cspan title=\"\"\u003eSelective inhibitors of COX-2 are not a substitute for aspirin for cardiovascular prophylaxis because no effect on platelets. \u003c\/span\u003e\u003cspan title=\"\"\u003eBecause etoricoxib, a member of that class, does not inhibit platelet aggregation should not be discontinued antiplatelet therapy.\u003cbr\u003e\u003cbr\u003e\u003c\/span\u003e\u003cspan title=\"\"\u003eThe risk of gastrointestinal adverse reactions (ulcers or other gastrointestinal complications) for etoricoxib, other selective inhibitors of COX-2 or NSAID, is greater when taken concomitantly with acetylsalicylic acid (even at low doses). \u003c\/span\u003e\u003cspan title=\"\"\u003eNot been adequately evaluated in long-term studies the relative difference in GI safety between selective inhibitors of COX-2 plus aspirin vs. \u003c\/span\u003e\u003cspan title=\"\"\u003eacetylsalicylic acid.\u003cbr\u003e\u003cbr\u003e\u003c\/span\u003e\u003cspan title=\"\"\u003eNot recommended ARCOXIA ® to treat patients with advanced renal disease. \u003c\/span\u003e\u003cspan title=\"\"\u003eClinical experience in patients with estimated creatinine clearance \u0026lt;30 ml \/ min is very limited. \u003c\/span\u003e\u003cspan title=\"\"\u003eIf you have to start treatment with Arcoxia ® in these patients, it is advisable to closely monitor your kidney function.\u003cbr\u003e\u003cbr\u003e\u003c\/span\u003e\u003cspan title=\"\"\u003eThe long-term administration of NSAIDs has resulted in renal papillary necrosis and other renal damage type. \u003c\/span\u003e\u003cspan title=\"\"\u003eRenal prostaglandins may have a compensatory role in maintaining renal perfusion. \u003c\/span\u003e\u003cspan title=\"\"\u003eTherefore, if renal perfusion is compromised, Arcoxia ® administration may decrease the formation of prostaglandins and secondary renal blood flow and thereby impair renal function. \u003c\/span\u003e\u003cspan title=\"\"\u003ePatients at greatest risk of this disorder are those who have significantly decreased renal function, uncompensated heart failure, or liver cirrhosis. \u003c\/span\u003e\u003cspan title=\"\"\u003eIn these patients should consider monitoring renal function. \u003c\/span\u003e\u003cspan title=\"\"\u003eAs with other drugs that inhibit prostaglandin synthesis, it is expected that the discontinuation of Arcoxia ®, the condition will return to before treatment.\u003cbr\u003e\u003cbr\u003e\u003c\/span\u003e\u003cspan title=\"\"\u003eCaution should be exercised when initiating treatment with Arcoxia ® in patients significantly dehydrated. \u003c\/span\u003e\u003cspan title=\"\"\u003eIt is advisable to rehydrate these patients before starting to administer ARCOXIA ®.\u003cbr\u003e\u003cbr\u003e\u003c\/span\u003e\u003cspan title=\"\"\u003eAs with other drugs that inhibit prostaglandin synthesis, some patients have presented ARCOXIA ® fluid retention, edema and hypertension. \u003c\/span\u003e\u003cspan title=\"\"\u003eKeep in mind the possibility of fluid retention, edema or hypertension when used ARCOXIA ® in patients with edema, hypertension or pre-existing heart failure. \u003c\/span\u003e\u003cspan title=\"\"\u003eEtoricoxib may be associated with more frequent and severe hypertension than other NSAIDs or selective inhibitors of COX-2, particularly with higher doses. \u003c\/span\u003e\u003cspan title=\"\"\u003eTherefore, it should pay special attention to monitoring blood pressure during treatment with etoricoxib, if blood pressure rises significantly, you can consider other treatment alternatives.\u003cbr\u003e\u003cbr\u003e\u003c\/span\u003e\u003cspan title=\"\"\u003ePhysicians should be aware that some patients may experience upper gastrointestinal ulcers or their complications regardless of treatment they are receiving. \u003c\/span\u003e\u003cspan title=\"\"\u003eAlthough the risk of gastrointestinal toxicity is not eliminated Arcoxia ®, the MEDAL Program results show that patients treated with Arcoxia ®, the risk of gastrointestinal toxicity with ARCOXIA ® 60 or 90 mg once daily is significantly less than with diclofenac 150\u003c\/span\u003e\u003cspan title=\"\"\u003emg per day. \u003c\/span\u003e\u003cspan title=\"\"\u003eIn clinical studies with ibuprofen and naproxen, the risk of upper gastrointestinal ulcers detected by endoscopy was lower in patients treated with Arcoxia ® 120 mg once daily than in those treated with nonselective NSAIDs. \u003c\/span\u003e\u003cspan title=\"\"\u003eAlthough the incidence of ulcers detected by endoscopy was low in patients treated with 120 mg of Arcoxia ®, was higher than in those receiving placebo. \u003c\/span\u003e\u003cspan title=\"\"\u003eUpper gastrointestinal ulcers have occurred or its complications in patients treated with Arcoxia ®. \u003c\/span\u003e\u003cspan title=\"\"\u003eThese events can occur at any time during use and without warning symptoms. \u003c\/span\u003e\u003cspan title=\"\"\u003eIrrespective of treatment, it is known that the risk of perforation, ulcer or gastrointestinal bleeding is higher in patients with a history of these disorders and over 65 years.\u003cbr\u003e\u003cbr\u003e\u003c\/span\u003e\u003cspan title=\"\"\u003eIn clinical trials have reported increases in alanine aminotransferase (ALT) and \/ or aspartate aminotransferase (AST) (approximately three or more times the upper limit of normal) in approximately 1% of patients treated \u003c\/span\u003e\u003cspan title=\"\"\u003eup to a year with 30, 60 and 90 mg daily ARCOXIA ®. \u003c\/span\u003e\u003cspan title=\"\"\u003eIn lots of active treatment compared with clinical trials, the incidence of these increases in ALAT and ASAT was similar in patients treated with 60 and 90 mg daily ARCOXIA ® and those treated with naproxen 1,000 mg daily, \u003c\/span\u003e\u003cspan title=\"\"\u003ebut significantly lower than in those treated with diclofenac 150 mg daily. \u003c\/span\u003e\u003cspan style=\"background-color: #e6ecf9;\" title=\"\"\u003eThese increases were stopped in patients treated with Arcoxia ® in approximately half of the cases stopped while patients were taking Arcoxia ®. \u003c\/span\u003e\u003cspan title=\"\"\u003eIn controlled clinical studies of Arcoxia ® 30 mg daily to ibuprofen 2,400 mg daily or celecoxib 200 mg daily, the incidence of increases in ALAT and ASAT was similar.\u003cbr\u003e\u003cbr\u003e\u003c\/span\u003e\u003cspan title=\"\"\u003eIn a patient with symptoms and \/ or signs suggesting liver dysfunction or had evidence of abnormal liver function should be investigated if the abnormality persists. \u003c\/span\u003e\u003cspan title=\"\"\u003eIf the abnormality persists (at three or more times the upper limit of normal values), discontinue the administration of ARCOXIA ®.\u003c\/span\u003e\u003c\/span\u003e\u003c\/div\u003e\n\u003cdiv style=\"font-family: arial; font-size: 12px; zoom: 1;\" dir=\"ltr\"\u003e\u003cspan lang=\"en\"\u003e\u003cspan title=\"\"\u003e\u003cbr\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/div\u003e\n\u003cdiv style=\"font-family: arial; font-size: 12px; zoom: 1;\" dir=\"ltr\"\u003e\n\u003cdiv style=\"border-left-color: #f5f5f5; background-image: initial; background-attachment: initial; background-origin: initial; background-clip: initial; background-color: #f5f5f5;\" id=\"gt-res-wrap\"\u003e\n\u003cdiv class=\"almost_half_cell\" id=\"gt-res-content\"\u003e\n\u003cdiv style=\"zoom: 1;\" dir=\"ltr\"\u003e\u003cspan style=\"font-size: 16px; color: #333333; min-height: 93px; display: block; padding: 8px;\" lang=\"en\" id=\"result_box\"\u003e\u003cspan class=\"hps\"\u003eDOSAGE AND\u003c\/span\u003e \u003cspan class=\"hps\"\u003eADMINISTRATION:\u003c\/span\u003e \u003cspan class=\"hps\"\u003eArcoxia\u003c\/span\u003e \u003cspan class=\"hps\"\u003e® is administered\u003c\/span\u003e \u003cspan class=\"hps\"\u003eorally.\u003c\/span\u003e \u003cspan class=\"hps\"\u003eArcoxia\u003c\/span\u003e \u003cspan class=\"hps\"\u003e® can be taken\u003c\/span\u003e\u003cspan class=\"hps\"\u003ewith or without food\u003c\/span\u003e\u003cspan\u003e.\u003c\/span\u003e\u003cbr\u003e\u003cbr\u003e\u003cspan class=\"hps\"\u003earthritis:\u003c\/span\u003e\u003cbr\u003e\u003cbr\u003e\u003cspan class=\"hps\"\u003eOsteoarthritis:\u003c\/span\u003e \u003cspan class=\"hps\"\u003eThe recommended dosage\u003c\/span\u003e \u003cspan class=\"hps\"\u003eis 30\u003c\/span\u003e \u003cspan class=\"hps\"\u003eor 60\u003c\/span\u003e \u003cspan class=\"hps\"\u003emg\u003c\/span\u003e \u003cspan class=\"hps\"\u003eonce a\u003c\/span\u003e \u003cspan class=\"hps\"\u003eday.\u003c\/span\u003e\u003cbr\u003e\u003cbr\u003e\u003cspan class=\"hps\"\u003eRheumatoid arthritis:\u003c\/span\u003e \u003cspan class=\"hps\"\u003eThe recommended dosage is\u003c\/span\u003e \u003cspan class=\"hps\"\u003e90 mg\u003c\/span\u003e \u003cspan class=\"hps\"\u003eonce a\u003c\/span\u003e \u003cspan class=\"hps\"\u003eday.\u003c\/span\u003e\u003cbr\u003e\u003cbr\u003e\u003cspan class=\"hps\"\u003eAnkylosing\u003c\/span\u003e \u003cspan class=\"hps\"\u003eSpondylitis\u003c\/span\u003e\u003cspan\u003e:\u003c\/span\u003e \u003cspan class=\"hps\"\u003eThe recommended dosage\u003c\/span\u003e \u003cspan class=\"hps\"\u003eis 90\u003c\/span\u003e \u003cspan class=\"hps\"\u003emg\u003c\/span\u003e \u003cspan class=\"hps\"\u003eonce a\u003c\/span\u003e \u003cspan class=\"hps\"\u003eday.\u003c\/span\u003e\u003cbr\u003e\u003cbr\u003e\u003cspan class=\"hps\"\u003eAcute gouty arthritis\u003c\/span\u003e\u003cspan\u003e:\u003c\/span\u003e \u003cspan class=\"hps\"\u003eThe recommended dosage\u003c\/span\u003e \u003cspan class=\"hps\"\u003eis 120\u003c\/span\u003e \u003cspan class=\"hps\"\u003emg\u003c\/span\u003e \u003cspan class=\"hps\"\u003eonce a\u003c\/span\u003e \u003cspan class=\"hps\"\u003eday.\u003c\/span\u003e \u003cspan class=\"hps\"\u003eThis dosage\u003c\/span\u003e \u003cspan class=\"hps\"\u003eshould be used only\u003c\/span\u003e \u003cspan class=\"hps\"\u003eduring\u003c\/span\u003e \u003cspan class=\"hps\"\u003ethe acute symptomatic period\u003c\/span\u003e\u003cspan\u003e, limited to\u003c\/span\u003e \u003cspan class=\"hps\"\u003ea maximum of 8\u003c\/span\u003e \u003cspan class=\"hps\"\u003edays of treatment.\u003c\/span\u003e\u003cbr\u003e\u003cbr\u003e\u003cspan class=\"hps\"\u003eanalgesia:\u003c\/span\u003e\u003cbr\u003e\u003cbr\u003e\u003cspan class=\"hps\"\u003eRelief\u003c\/span\u003e \u003cspan class=\"hps\"\u003eof acute pain and\u003c\/span\u003e \u003cspan class=\"hps\"\u003eprimary dysmenorrhea:\u003c\/span\u003e \u003cspan class=\"hps\"\u003eThe recommended dosage\u003c\/span\u003e \u003cspan class=\"hps\"\u003eis 120\u003c\/span\u003e \u003cspan class=\"hps\"\u003emg\u003c\/span\u003e \u003cspan class=\"hps\"\u003eonce a\u003c\/span\u003e \u003cspan class=\"hps\"\u003eday.\u003c\/span\u003e \u003cspan class=\"hps\"\u003eThis dosage\u003c\/span\u003e \u003cspan class=\"hps\"\u003eshould be used only\u003c\/span\u003e \u003cspan class=\"hps\"\u003eduring\u003c\/span\u003e \u003cspan class=\"hps\"\u003ethe acute symptomatic period\u003c\/span\u003e\u003cspan\u003e, limited to\u003c\/span\u003e \u003cspan class=\"hps\"\u003ea maximum of 8\u003c\/span\u003e \u003cspan class=\"hps\"\u003edays of treatment.\u003c\/span\u003e\u003cbr\u003e\u003cbr\u003e\u003cspan class=\"hps\"\u003eChronic Pain:\u003c\/span\u003e \u003cspan class=\"hps\"\u003eThe recommended dosage\u003c\/span\u003e \u003cspan class=\"hps\"\u003eis 60\u003c\/span\u003e \u003cspan class=\"hps\"\u003emg\u003c\/span\u003e \u003cspan class=\"hps\"\u003eonce a\u003c\/span\u003e \u003cspan class=\"hps\"\u003eday.\u003c\/span\u003e\u003c\/span\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MSD","offers":[{"title":"Default Title","offer_id":168057072,"sku":"FDN-00138","price":1714.68,"currency_code":"MXN","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0111\/7372\/products\/arcoxia-etoricoxib-90mg-14tab_fcaea3ca-ddb2-41b6-96d0-1018598654e6.jpg?v=1672782488","url":"https:\/\/www.farmaciasdelnino.com.mx\/products\/arcoxia-etoricoxib-90mg-14tab","provider":"FARMACIA DEL NIÑO","version":"1.0","type":"link"}